Tempus AI partners with Bristol Myers Squibb to enhance clinical trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TEM?
Tempus AI Inc. saw a decline of 3.01% as it hit a 20-day low amid broader market weakness, with the Nasdaq-100 down 1.18% and the S&P 500 down 0.87%.
The company's recent partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs across five initial programs. This collaboration is expected to enhance the Probability of Technical & Regulatory Success (PTRS) and improve drug development efficiency, particularly in oncology and neuroscience, including solid tumors and Alzheimer's disease drug development.
This strategic collaboration highlights Tempus' commitment to innovation in clinical research, potentially positioning the company for future growth as it seeks to improve patient outcomes through data-driven decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 45.480
Low
76.00
Averages
84.38
High
105.00
Current: 45.480
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Ambry Genetics Wins Best Health Informatics Solution Award
- Award Recognition: Ambry Genetics' CARE program was awarded 'Best Overall Health Informatics Solution' at the 10th Annual MedTech Breakthrough Awards, standing out among over 5,000 global nominations, highlighting its excellence in digital health and medical technology.
- Risk Assessment Innovation: The CARE program integrates with electronic health records (EHR) to help health systems identify patients at increased risk for breast cancer, providing personalized education and streamlining the entire genetic testing process, thereby enhancing clinical workflow efficiency and patient care quality.
- Clinical Workflow Optimization: By directly connecting patients with certified genetic counselors, the program enables clinicians to understand patient risks before visits, promoting personalized care and earlier cancer detection, which significantly improves health outcomes for patients.
- Strategic Commitment: Tempus CEO emphasized that the CARE program not only simplifies patient education processes but also demonstrates the company's strong commitment to integrating clinical workflows and delivering more proactive personalized care, which is expected to have a lasting impact on high-risk patient care.
See More
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Ambry Genetics Wins Best Health Informatics Solution Award
- Award Recognition: Ambry Genetics' CARE program was awarded 'Best Overall Health Informatics Solution' at the 10th Annual MedTech Breakthrough Awards, standing out among over 5,000 global nominations, highlighting its excellence in digital health and medical technology.
- Risk Assessment Innovation: The CARE program integrates with electronic health records (EHR) to help health systems identify patients at increased risk for breast cancer, providing personalized education and streamlining the entire genetic testing process, thereby enhancing clinical workflow efficiency and patient care quality.
- Clinical Workflow Optimization: By directly connecting patients with certified genetic counselors, the program enables clinicians to understand patient risks before visits, promoting personalized care and earlier cancer detection, which significantly improves health outcomes for patients.
- Strategic Commitment: Tempus CEO emphasized that the CARE program not only simplifies patient education processes but also demonstrates the company's strong commitment to integrating clinical workflows and delivering more proactive personalized care, which is expected to have a lasting impact on high-risk patient care.
See More
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
